Peptides

CagriSema Research Overview

Research overview of CagriSema, the semaglutide plus cagrilintide combination studied for enhanced weight loss and metabolic outcomes.

CagriSema Research Overview

CagriSema is a fixed-dose combination research compound comprising semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analogue). Developed as part of the next wave of incretin and metabolic research, CagriSema is designed to engage two complementary hormonal pathways simultaneously. The combination is currently in Phase 3 clinical trials and represents a novel dual-hormone approach to metabolic research.

Mechanism of Action: Two Hormonal Pathways

Semaglutide (GLP-1 Receptor Agonist)

Semaglutide is a well-characterised GLP-1 receptor agonist that researchers have observed to act on multiple physiological pathways:

  • Stimulates glucose-dependent insulin secretion
  • Suppresses glucagon release
  • Slows gastric emptying
  • Acts on central appetite centres to reduce food intake

For a detailed overview of semaglutide’s mechanism and clinical data, see the Semaglutide research page.

Cagrilintide (Amylin Analogue)

Cagrilintide is a long-acting acylated amylin analogue. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic β-cells. Native amylin acts on the amylin receptor (a calcitonin receptor-based receptor) in the brainstem and hypothalamus to promote satiety, slow gastric emptying, and suppress postprandial glucagon.

Cagrilintide has been designed for extended half-life through albumin binding, enabling once-weekly dosing — a significant improvement over pramlintide (an earlier amylin analogue requiring multiple daily injections). Researchers have observed that cagrilintide’s mechanism is largely complementary to GLP-1 RAs, as the amylin and GLP-1 receptor systems exert overlapping but distinct effects on appetite regulation and glycaemic control.

The Dual-Hormone Rationale

The combination of a GLP-1 RA with an amylin analogue is based on the hypothesis that engaging both hormonal pathways produces additive or synergistic effects. Researchers have observed that:

  • GLP-1 and amylin receptors are expressed in overlapping but distinct brain regions involved in appetite regulation
  • The two pathways may reduce food intake through complementary mechanisms (e.g., GLP-1 acting more on reward-driven eating, amylin more on meal-size signalling)
  • Combined gastric emptying effects may enhance postprandial glycaemic control
  • Cagrilintide may contribute to weight loss independent of the nausea commonly associated with higher GLP-1 RA doses

This dual-hormone approach differs from dual-receptor agonism (as with tirzepatide) by using two distinct molecules targeting two different receptor systems.

REDEFINE Clinical Trial Programme

The REDEFINE programme is a series of Phase 3 trials evaluating CagriSema for weight management and related metabolic outcomes:

  • REDEFINE 1 (n=~3,400): A pivotal trial in adults with obesity or overweight (without diabetes), comparing CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) against its individual components and placebo. Researchers reported that CagriSema achieved significantly greater weight loss than either semaglutide or cagrilintide alone at 68 weeks. Top-line results indicated approximately 22.7% mean weight reduction with CagriSema versus 15.4% with semaglutide alone.
  • REDEFINE 2: Evaluated CagriSema in adults with type 2 diabetes and overweight/obesity, assessing both HbA1c and weight endpoints.
  • REDEFINE 3: A dedicated cardiovascular outcomes trial designed to assess MACE in adults with established cardiovascular disease and obesity.
  • REDEFINE 4 and beyond: Additional trials examining different dosing strategies, combination approaches, and longer-term safety profiles.

REVOKE Trial Programme

The REVOKE trials investigate CagriSema in broader metabolic contexts:

  • REVOKE 1: Focused on adults with metabolic dysfunction-associated steatohepatitis (MASH), examining hepatic fat reduction and histological endpoints.
  • REVOKE 2: Investigating CagriSema in heart failure with preserved ejection fraction (HFpEF) in people with obesity.

Why the Dual-Hormone Approach Matters

The development of CagriSema reflects a broader trend in metabolic research toward combination approaches that target multiple hormonal pathways simultaneously. Several observations have driven this direction:

  • Ceiling effects with single-pathway agents: While GLP-1 RAs like semaglutide have shown substantial efficacy, there is interest in whether combining mechanisms can push beyond the weight loss plateau observed with higher GLP-1 RA doses.
  • Complementary safety profiles: Researchers have hypothesised that the combination may allow lower doses of each component while maintaining or improving efficacy, potentially reducing dose-dependent side effects.
  • Distinct physiological roles of amylin: Amylin signalling has independent effects on satiety, gastric motility, and glucagon suppression that are not fully replicated by GLP-1 receptor activation alone.
  • Head-to-head data emerging: Early comparisons suggest CagriSema may achieve greater weight loss than semaglutide 2.4 mg monotherapy, supporting the additive mechanism hypothesis.

Research Status

CagriSema is currently in Phase 3 clinical trials. Key aspects of its development status:

  • The REDEFINE programme is ongoing, with several trials in enrolment or follow-up phases
  • Regulatory submissions have not yet been made in Australia or globally
  • Long-term safety data beyond two years is still being collected
  • The combination is being investigated across multiple indications beyond obesity, including MASH and heart failure

No TGA approval or PBS listing exists for CagriSema in Australia at this time. The compound remains investigational.

Researchers interested in CagriSema may also wish to explore:

  • Semaglutide — the GLP-1 RA component of CagriSema, with extensive clinical trial data
  • [Retatrutide](/peptides/retatrutide/] — a triple GIP/GLP-1/glucagon receptor agonist representing another multi-pathway approach
  • Tirzepatide — the dual GIP/GLP-1 RA, another major multi-agonist compound

Disclaimer: This page is for research and educational purposes only. No therapeutic claims are made. CagriSema is an investigational compound and is not approved for therapeutic use in Australia. This information does not constitute medical advice. Consult a qualified healthcare professional for any health-related decisions. All data referenced is drawn from published peer-reviewed clinical trials and publicly disclosed trial results.